Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Temozolomide is the standard adjuvant chemotherapy of newly-diagnosis malignant
gliomas.Cisplatin , a kind of chemotherapeutics, can enforce the anti-tumor effects of TMZ.
Up to now, the prognosis of recurrent gliomas is very pessimistic and the standard treatment
procedure has not been established yet.
The prospective,multicentre phase II clinical study is to evaluate the efficacy and safety of
TMZ and CDDP in patients with recurrent malignant gliomas
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Beijing Tiantan Hospital Tianjin Medical University General Hospital